DNA-binding studies with 6BT and 5I: implications for DNA-binding/carcinogenicity and DNA-binding/mutagenicity correlations

This publication has 17 references indexed in Scilit:

• Deficiencies in the covalent binding idnex (CBI) for expressing in vivo binding to DNA with respect to predicting chemical carcinogenicity: A proposal for a target-organ binding index
  Mutation Research Letters, 1987
• The use of in vivo-like concentrations of chemicals for validation of in vitro short-term genotoxicity assays - an in vivo equivalent dose concept
  Mutagenesis, 1987
• The disposition and in vivo covalent binding to liver DNA of the monoazodyes 6-(p-dimethylaminophenylazo)benzothiazole (6BT) and 5-(p-dimethylaminophenylazo) indazole (51) after administration to the rat
  Carcinogenesis: Integrative Cancer Research, 1986
• Mutagenicity to Salmonella of four derivatives of the azo mutagen 5I: some implications for structure—activity databases and the evaluation of combinations of mutagens
  Mutagenesis, 1986
• An assessment of the in vivo rat hepatocyte DNA-repair assay
  Mutation Research/Genetic Toxicology, 1985
• The possible role of azoreduction in the bacterial mutagenicity of 4-dimethylaminoazobenzene (DAB) and 2 of its analogues (6BT and 5I)
  Mutation Research/Genetic Toxicology, 1983
• A review of the genotoxicity of food, drug and cosmetic colours and other azo, triphenylmethane and xanthene dyes
  Mutation Research/Reviews in Genetic Toxicology, 1982
• Limitations of Metabolic Activation Systems Used with in Vitro Tests for Carcinogens
  Science, 1980
• Carcinogenic activity of analogs of p-dimethylaminoazobenzene. IX. Activity of the quinoxaline and indazole analogs
  Journal of Medicinal Chemistry, 1969
• Carcinogenic activity of analogs of p-dimethylaminoazobenzene. VI. Activity of the benzimidazole and benzthiazole analogs
  Journal of Medicinal Chemistry, 1968